Lucy Hicks - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Lucy Hicks's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Lucy Hicks
Verified
Reporter, Medscape
Boston
Beats
Human interest and GenderHuman rightsSocial justice
Content
By Lucy Hicks| Medscape Verified Biologics are more effective at treating adult-onset Still’s disease (AOSD) than glucocorticoids or conventional disease-modifying antirheumatic drugs (DMARDs), according to a new retrospective study. Half of the patients treated with first-line biologic DMARDs achieved sustained, event-free remission compared with 12% of patients in the conventional therapy group
By Lucy Hicks| Medscape Verified The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the first and only treatment approved for this rare autoimmune disease in the United States. An estimated 200,000 people in the United States are living with IgG4-RD, according to a press release from Amgen
Company Info
Medscape
Boston, United States